This prolongs feelings of fullness, reducing the urge to snack between meals and lowering calorie intake
This is because extra fat tissue, especially around the belly, changes how hormones are made and used in the body
2 The SELECT trial kidney outcomes The SELECT trial tested semaglutide at the Wegovy dose (2.4 mg) in 17,604 people with obesity and cardiovascular disease, without diabetes
It states plainly that direct gut healing is not established in the clinical literature and that semaglutide is not a gut-healing agent
But when doctors do prescribe them for overlapping metabolic issues (such as insulin resistance or obesity), the most commonly recommended medications include: Semaglutide (Ozempic/Wegovy) Tirzepatide (Mounjaro/Zepbound) technically a GLP-1 + GIP dual agonist Liraglutide (Saxenda) The choice depends on: How severe metabolic symptoms are Tolerance to side effects Cost and insurance status The clinicians expertise One study looking at GLP-1associated fat changes noted that visceral fat reduction can significantly improve inflammatory biomarkers, as shown in an adipose tissue study
This past spring, multiple officials inside the agency expressed concern that then FDA head Marty Zakary was stacking the hearing with panelists who had direct connections to the peptide industry, according to reporting from the Washington Post published last week
